Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984393 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL6890292 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL11767115 | 0.89 | SOAT1 (0.62) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL10344105 | 0.86 | ALDH1A1 (0.55) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL31731277 | 0.86 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPT | |
| SCHEMBL25382868 | 0.85 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPTL3MBTL1 | |
| SCHEMBL149834 | 0.85 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPTL3MBTL1 | |
| SCHEMBL2984199 | 0.85 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPTL3MBTL1 | |
| SCHEMBL2980293 | 0.85 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPTL3MBTL1 | |
| SCHEMBL25380452 | 0.85 | MAPT (0.38) | ALDH1A1SOAT1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324272-B2 | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | claimed |
| US-8324272-B2 | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709527-B2 | 2-acetyloxy-1-methylpropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Parkinson's disease; crystalline forms; improved pharmacokinetics; oral administration | XENOPORT, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2125702-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | Xenoport, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008076458-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | XENOPORT, INC. | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, DDT, DDC | ALDH1A1 996/4885SOAT1 3532/4885LMNA 2422/4885 |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | COMT, DDT, DDC | ALDH1A1 893/4885SOAT1 3560/4885LMNA 2510/4885 |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | COMT, CHAT, SLC6A3 | ALDH1A1 1594/4885SOAT1 2670/4885LMNA 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.